# Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

> **NCT00002572** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 10 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** muromonab-CD3
- **BIOLOGICAL:** therapeutic tumor infiltrating lymphocytes
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00002572
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-11
- **Primary completion:** 1999-12
- **Final completion:** 1999-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2013-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002572, "Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*